ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Record History

See every version on ClinicalTrials.gov ↗

1. Minor Changed Oct 4, 2026 Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Active, Not Recruiting
2. Notable Jun 12, 2024 Primary completion date changed from estimate of Mar 30, 2023 to Mar 31, 2024v4 Show 5 more changesShow less

   • Trial status: Recruiting to Active, Not Recruiting
   • Enrollment target: estimated 334 to confirmed 337
   • Study completion date: Dec 30, 2023 to Sep 30, 2026
   • Eligibility criteria expanded, about 710 words
   • Site details revised at 3 of 3 sites
3. Notable May 8, 2022 Primary completion date: Jan 2021 to Mar 30, 2023

   • Study completion date: Aug 2021 to Dec 30, 2023
   • Eligibility criteria shortened, about 19 words

   v3
4. Minor Nov 20, 2019 Interventions: ASK120067 + placebo (Drug), Gefitinib + placebo ASK120067 (Drug), Gefitinib 250 mg (Drug), Placebo ASK120067 (Drug), Placebo Gefitinib 250… to ASK120067 (Drug), Gefitinib (Drug), Placebo ASK120067 (Drug), Placebo Gefitinib 250 mg (Drug)

   • Secondary endpoints: details revised at 3 of 5 entries
   • Site details revised at 1 of 3 sites
   • Study title shortened, about 1 word

   v2
5. Minor Oct 28, 2019 Study First Submitted

• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.